AMBU-B Stock Analysis: Ambu | CO
Medical Devices | CO, Denmark | Market Cap: 18.408m DKK | 12M Return: -30.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 50.1M
EPS Trend: 80.5%
Qual. Beats: -1
Rev. Trend: 98.4%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ambu A/S is a Danish medical technology company that researches, develops, manufactures, markets, and sells healthcare equipment and solutions across North America, Europe, and international markets. Its product portfolio spans several clinical areas: endoscopy (including single-use bronchoscopes, laryngoscopes, and other scopes), neurology (EEG/EMG electrodes and intraoperative monitoring), cardiology (ECG electrodes), airway management and anaesthesia (tubes, masks, breathing bags, resuscitators), and emergency care and training products (such as extrication collars and training manikins).
The company is headquartered in Ballerup, Denmark, and was founded in 1937, giving it nearly a century of operating history in the medical device industry. As a player in the healthcare equipment sector, Ambu is positioned to benefit from the broader industry trend toward single-use disposable endoscopy devices, which aim to reduce cross-contamination risk and eliminate the need for device reprocessing between procedures.
- Single-use endoscopy volume growth offsets reusable market competition
- China market softness pressures revenue and gross margins
- FDA single-use duodenoscope mandates support U.S. visualization sales
| Net Income: 477.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 1.25 > 1.0 |
| NWC/Revenue: 32.45% < 20% (prev 32.36%; Δ 0.09% < -1%) |
| CFO/TA 0.11 > 3% & CFO 847.0m > Net Income 477.0m |
| Net Debt (-140.0m) to EBITDA (1.04b): -0.13 < 3 |
| Current Ratio: 2.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (266.6m) vs 12m ago 0.67% < -2% |
| Gross Margin: 55.82% > 18% (prev 60.27%; Δ -4.45% > 0.5%) |
| Asset Turnover: 81.28% > 50% (prev 78.69%; Δ 2.59% > 0%) |
| Interest Coverage Ratio: 10.90 > 6 (EBIT TTM 654.0m / Interest Expense TTM 60.0m) |
| A: 0.26 (Total Current Assets 3.01b - Total Current Liabilities 1.03b) / Total Assets 7.61b |
| B: 0.77 (Retained Earnings 5.86b / Total Assets 7.61b) |
| C: 0.09 (EBIT TTM 654.0m / Avg Total Assets 7.51b) |
| D: 4.05 (Book Value of Equity 6.10b / Total Liabilities 1.50b) |
| Altman-Z'' = 9.06 = AAA |
| DSRI: 0.99 (Receivables 948.0m/911.0m, Revenue 6.10b/5.83b) |
| GMI: 1.08 (GM 60.27% / 55.82%) |
| AQI: 0.96 (AQ_t 0.45 / AQ_t-1 0.46) |
| SGI: 1.05 (Revenue 6.10b / 5.83b) |
| TATA: -0.05 (NI 477.0m - CFO 847.0m) / TA 7.61b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of July 29, 2026, the stock is trading at DKK 70.10 with a total of 575,307 shares traded. Over the past week, the price has changed by -1.61%, over one month by +14.17%, over three months by +8.01% and over the past year by -30.54%.
Current recommended Stop Loss: 67.70 (which is 3.4% or 1.2 ATR below the current price).
Ambu has no consensus analysts rating.
P/E Trailing = 39.1899
P/E Forward = 24.2131
P/S = 3.0158
P/B = 3.0669
P/EG = 2.8489
Revenue TTM = 6.10b DKK
EBIT TTM = 654.0m DKK
EBITDA TTM = 1.04b DKK
Long Term Debt = 17.0m DKK (from longTermDebt, last quarter)
Short Term Debt = 85.0m DKK (from shortTermDebt, last quarter)
Debt = 551.0m DKK (from shortLongTermDebtTotal, last quarter) (leases 534.0m already included)
Net Debt = -140.0m DKK (calculated: Debt 551.0m - CCE 691.0m)
Enterprise Value = 18.3b DKK (18.4b + Debt 551.0m - CCE 691.0m)
Interest Coverage Ratio = 10.90 (Ebit TTM 654.0m / Interest Expense TTM 60.0m)
EV/FCF = 35.40x (Enterprise Value 18.3b / FCF TTM 516.0m)
FCF Yield = 2.82% (FCF TTM 516.0m / Enterprise Value 18.3b)
FCF Margin = 8.45% (FCF TTM 516.0m / Revenue TTM 6.10b)
Net Margin = 7.81% (Net Income TTM 477.0m / Revenue TTM 6.10b)
Gross Margin = 55.82% ((Revenue TTM 6.10b - Cost of Revenue TTM 2.70b) / Revenue TTM)
Gross Margin QoQ = 60.27% (prev 60.78%)
Tobins Q-Ratio = 2.40 (Enterprise Value 18.3b / Total Assets 7.61b)
Interest Expense / Debt = 10.89% (Interest Expense 60.0m / Debt 551.0m)
Taxrate = 23.06% (143.0m / 620.0m)
NOPAT = 503.2m (EBIT 654.0m * (1 - 23.06%))
Current Ratio = 2.92 (Total Current Assets 3.01b / Total Current Liabilities 1.03b)
Debt / Equity = 0.09 (Debt 551.0m / totalStockholderEquity, last quarter 6.10b)
Debt / EBITDA = -0.13 (Net Debt -140.0m / EBITDA 1.04b)
Debt / FCF = -0.27 (Net Debt -140.0m / FCF TTM 516.0m)
Total Stockholder Equity = 6.02b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.35% (Net Income 477.0m / Total Assets 7.61b)
RoE = 7.92% (Net Income TTM 477.0m / Total Stockholder Equity 6.02b)
RoCE = 10.83% (EBIT 654.0m / Capital Employed (Equity 6.02b + L.T.Debt 17.0m))
RoIC = 7.92% (NOPAT 503.2m / Invested Capital 6.35b)
WACC = 8.22% (E(18.4b)/V(19.0b) * Re(8.22%) + D(551.0m)/V(19.0b) * Rd(10.89%) * (1-Tc(0.23)))
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 15.47 | Cagr: 0.04%
[DCF] Terminal Value 77.97% ; FCFF base≈473.6m ; Y1≈542.9m ; Y5≈799.0m
[DCF] Fair Price = 53.33 (EV 12.0b - Net Debt -140.0m = Equity 12.2b / Shares 228.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 80.47 | EPS CAGR: 68.17% | SUE: -1.36 | # QB: -1
Revenue Correlation: 98.38 | Revenue CAGR: 11.42% | SUE: -2.02 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.62 | Chg30d=-0.93% | Revisions=-40% | Analysts=2
EPS current Year (2026-09-30): EPS=2.30 | Chg30d=-0.29% | Revisions=+25% | GrowthEPS=+1.0% | GrowthRev=+7.0%
EPS next Year (2027-09-30): EPS=3.08 | Chg30d=+0.03% | Revisions=-25% | GrowthEPS=+33.9% | GrowthRev=+11.2%
[Analyst] Revisions Ratio: -29% (up=1, down=3)